QDEL
QuidelOrtho Corporation
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-25/100
Last price
12.38
▲ 0.24 (1.98%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
12.14
Prev close
12.14
Day high
13.09
Day low
12.15
Volume
3.22M
Market cap
$861.99M
P/E (TTM)
—
52W range
9.92 – 35.58
Day trading desk
Gap from prior close
-0.00%
Prior close 12.14
VWAP
12.56
-1.44% from price
Relative volume
3.92×
Unusually busy
Session range
19.00%
11.00 – 13.09
Position in range
66%
Mid range
ATR (14D)
0.70
5.61% of price
Prior day high
12.51
PDH
Prior day low
10.52
PDL
Bid / ask spread
—
Quote not published
Session volume
5.80M
Avg 1.48M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+18.58%
+16.6%
1M
-10.02%
-11.2%
3M
-27.13%
-31.7%
6M
-16.09%
-34.3%
YTD
-55.99%
-70.2%
1Y
-58.07%
-74.5%
3Y
-82.79%
-165.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on QDEL open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
616.49K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 14, 26 | HANSON BRYAN MICHAEL Officer |
— | 446 | — | Direct |
| Jul 1, 26 | HANSON BRYAN MICHAEL Officer |
— | 5.80K | — | Direct |
| Jun 5, 26 | POLAN MARY LAKE PH.D Director |
STOCK | 973 | $0 | Direct |
| Jun 5, 26 | WIDDER KENNETH JON M.D. Director |
STOCK | 1.18K | $0 | Direct |
| Jun 5, 26 | MICHAEL EDWARD L Director |
STOCK | 1.25K | $0 | Direct |
| Jun 5, 26 | BUECHLER KENNETH F Director |
STOCK | 2.16K | $0 | Direct |
| Jun 5, 26 | MICHAEL EDWARD L Director |
CONVERSION | 963 | $13.80K | Direct |
| Jun 5, 26 | POLAN MARY LAKE PH.D Director |
CONVERSION | 749 | $10.73K | Direct |
| Jun 5, 26 | WIDDER KENNETH JON M.D. Director |
CONVERSION | 910 | $13.04K | Direct |
| Jun 5, 26 | BUECHLER KENNETH F Director |
CONVERSION | 1.66K | $23.77K | Direct |
| May 29, 26 | WILKINS JOSEPH D JR Director |
STOCK | 6.83K | $0 | Direct |
| May 29, 26 | CHIMINSKI JOHN R Director |
STOCK | 6.83K | $0 | Direct |
| May 29, 26 | POLAN MARY LAKE PH.D Director |
STOCK | 6.83K | $0 | Direct |
| May 29, 26 | WIDDER KENNETH JON M.D. Director |
STOCK | 6.83K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BLASER BRIAN J |
Chief Executive Officer | 75.72K | Stock Award(Grant) |
BUECHLER KENNETH F |
Director | 110.91K | Stock Award(Grant) |
BUJARSKI ROBERT JOSEPH |
Chief Operating Officer | 44.81K | Stock Award(Grant) |
BUSKY JOSEPH M |
Chief Financial Officer | 55.11K | Stock Award(Grant) |
HODGES MICHELLE A |
Officer | 41.60K | Stock Award(Grant) |
MICHAEL EDWARD L |
Director | 29.43K | Stock Award(Grant) |
POLAN MARY LAKE PH.D |
Director | 37.80K | Stock Award(Grant) |
RHOADS ANN D |
Director | 23.26K | Stock Award(Grant) |
STROBECK MATTHEW |
Director | 89.38K | Stock Award(Grant) |
WIDDER KENNETH JON M.D. |
Director | 45.07K | Stock Award(Grant) |
Fundamentals
Market cap$861.99M
Enterprise value$3.81B
Revenue (TTM)$2.67B
Gross profit$1.20B
EBITDA$484.60M
Net income$-1.05B
EPS (TTM)$-15.96
Free cash flow$146.76M
Total cash$123.40M
Total debt$3.08B
Book value / share$25.99
Shares outstanding68.58M
Float61.17M
Short % of float28.21%
Dividend yield0.00%
Beta (5Y)0.78
Valuation & profitability ratios
Trailing P/E—
Forward P/E8.72
PEG ratio2.06
Price / sales—
Price / book0.48
EV / revenue1.43
EV / EBITDA7.87
Gross margin44.86%
Operating margin-2.09%
Profit margin-39.20%
Return on equity-45.91%
Return on assets0.38%
Debt / equity173.28
Current ratio1.39
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.73B | $2.78B | $3.00B | $3.27B | -1.9% |
| Operating revenue | $2.73B | $2.78B | $3.00B | $3.27B | -1.9% |
| Cost of revenue | $1.46B | $1.50B | $1.50B | $1.33B | -2.7% |
| Gross profit | $1.27B | $1.29B | $1.50B | $1.94B | -1.0% |
| Research & development | $186.20M | $218.70M | $245.00M | $187.90M | -14.9% |
| Selling, general & admin | $746.30M | $766.80M | $763.20M | $621.00M | -2.7% |
| Total operating expense | $1.22B | $1.24B | $1.24B | $953.70M | -1.7% |
| Operating income | $54.80M | $45.80M | $257.00M | $982.50M | +19.7% |
| Net interest income | -$185.60M | -$188.90M | -$176.70M | -$75.30M | +1.7% |
| Pre-tax income | -$1.11B | -$2.13B | -$29.10M | $735.90M | +48.0% |
| Tax provision | $24.10M | -$79.50M | -$19.00M | $187.20M | +130.3% |
| Net income | -$1.13B | -$2.05B | -$10.10M | $548.70M | +44.8% |
| Net income to common | -$1.13B | -$2.05B | -$10.10M | $548.70M | +44.8% |
| Basic EPS | -16.69 | -30.16 | -0.15 | 9.66 | +44.7% |
| Diluted EPS | -16.69 | -30.16 | -0.15 | 9.56 | +44.7% |
| EBIT | -$924.60M | -$1.94B | $149.80M | $810.40M | +52.4% |
| EBITDA | -$482.60M | -$1.49B | $607.00M | $1.09B | +67.6% |
| Basic shares | 67.80M | 67.20M | 66.80M | 56.80M | +0.9% |
| Diluted shares | 67.80M | 67.20M | 66.80M | 57.40M | +0.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $169.80M | $98.30M | $118.90M | $292.90M | +72.7% |
| Cash & short-term investments | $169.80M | $98.30M | $167.30M | $345.00M | +72.7% |
| Accounts receivable | $417.00M | $282.40M | $303.30M | $453.90M | +47.7% |
| Inventory | $577.60M | $533.70M | $577.80M | $524.10M | +8.2% |
| Total current assets | $1.45B | $1.22B | $1.31B | $1.58B | +18.7% |
| Property, plant & equipment | $1.51B | $1.55B | $1.61B | $1.52B | -2.3% |
| Goodwill & intangibles | $2.56B | $3.39B | $5.43B | $5.60B | -24.3% |
| Total assets | $5.77B | $6.42B | $8.56B | $8.86B | -10.2% |
| Total current liabilities | $966.10M | $998.80M | $833.80M | $1.01B | -3.3% |
| Current debt | $178.30M | $341.80M | $139.80M | $207.50M | -47.8% |
| Long-term debt | $2.47B | $2.14B | $2.27B | $2.43B | +15.4% |
| Total debt | $2.83B | $2.68B | $2.61B | $2.85B | +5.7% |
| Total liabilities | $3.85B | $3.44B | $3.56B | $3.92B | +11.9% |
| Retained earnings | -$996.00M | $135.80M | $2.19B | $2.20B | -833.4% |
| Shareholder equity | $1.92B | $2.98B | $5.01B | $4.93B | -35.7% |
| Working capital | $481.20M | $220.10M | $476.70M | $568.10M | +118.6% |
| Net tangible assets | -$643.30M | -$400.60M | -$420.40M | -$666.00M | -60.6% |
| Shares issued | 67.93M | 67.26M | 66.70M | 66.40M | +1.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$1.13B | -$2.05B | -$10.10M | $548.70M | +44.8% |
| Depreciation & amortisation | $442.00M | $453.40M | $457.20M | $283.60M | -2.5% |
| Stock-based compensation | $45.90M | $42.10M | $51.60M | $48.40M | +9.0% |
| Change in working capital | -$125.80M | -$158.70M | -$194.90M | -$53.20M | +20.7% |
| Operating cash flow | $105.20M | $83.00M | $280.20M | $885.30M | +26.7% |
| Capital expenditure | -$188.20M | -$195.10M | -$209.30M | -$140.90M | +3.5% |
| Investing cash flow | -$192.70M | -$149.90M | -$187.60M | -$1.64B | -28.6% |
| Share buybacks | $0 | $0 | -$7.20M | -$74.30M | — |
| Financing cash flow | $155.80M | $48.80M | -$265.80M | $252.00M | +219.3% |
| Free cash flow | -$83.00M | -$112.10M | $70.90M | $744.40M | +26.0% |
| End cash position | $169.80M | $98.50M | $119.50M | $293.90M | +72.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $630.90M | $619.80M | $723.60M | $699.90M | $613.90M | +1.8% |
| Operating revenue | $630.90M | $619.80M | $723.60M | $699.90M | $613.90M | +1.8% |
| Cost of revenue | $358.00M | $356.00M | $403.20M | $364.30M | $339.00M | +0.6% |
| Gross profit | $272.90M | $263.80M | $320.40M | $335.60M | $274.90M | +3.4% |
| Research & development | $48.70M | $44.90M | $45.80M | $41.50M | $45.70M | +8.5% |
| Selling, general & admin | $189.70M | $199.30M | $194.40M | $186.90M | $178.00M | -4.8% |
| Total operating expense | $288.20M | $291.20M | $357.70M | $290.40M | $276.70M | -1.0% |
| Operating income | -$15.30M | -$27.40M | -$37.30M | $45.20M | -$1.80M | +44.2% |
| Net interest income | -$52.60M | -$49.10M | -$51.50M | -$48.60M | -$43.00M | -7.1% |
| Pre-tax income | -$81.20M | -$79.50M | -$112.40M | -$756.90M | -$229.60M | -2.1% |
| Tax provision | $11.70M | $12.30M | $18.30M | -$23.90M | $25.80M | -4.9% |
| Net income | -$92.90M | -$91.80M | -$130.70M | -$733.00M | -$255.40M | -1.2% |
| Net income to common | -$92.90M | -$91.80M | -$130.70M | -$733.00M | -$255.40M | -1.2% |
| Basic EPS | -1.36 | -1.35 | -1.92 | -10.78 | -3.77 | -0.7% |
| Diluted EPS | -1.36 | -1.35 | -1.92 | -10.78 | -3.77 | -0.7% |
| EBIT | -$30.30M | -$31.50M | -$62.30M | -$709.10M | -$186.70M | +3.8% |
| EBITDA | $86.40M | $81.40M | $50.20M | -$597.00M | -$76.40M | +6.1% |
| Basic shares | 68.30M | 68.20M | 68.00M | 68.00M | 67.70M | +0.1% |
| Diluted shares | 68.30M | 68.20M | 68.00M | 68.00M | 67.70M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $123.40M | $140.40M | $169.80M | $98.10M | $151.70M | -12.1% |
| Cash & short-term investments | $123.40M | $140.40M | $169.80M | $98.10M | $151.70M | -12.1% |
| Accounts receivable | $352.00M | $359.90M | $417.00M | $386.50M | $275.00M | -2.2% |
| Inventory | $618.90M | $611.50M | $577.60M | $613.80M | $578.70M | +1.2% |
| Total current assets | $1.38B | $1.38B | $1.45B | $1.37B | $1.28B | -0.0% |
| Property, plant & equipment | $1.49B | $1.50B | $1.51B | $1.48B | $1.47B | -0.2% |
| Goodwill & intangibles | $2.68B | $2.52B | $2.56B | $2.61B | $3.37B | +6.3% |
| Total assets | $5.72B | $5.63B | $5.77B | $5.68B | $6.38B | +1.5% |
| Total current liabilities | $993.40M | $962.40M | $966.10M | $767.90M | $1.14B | +3.2% |
| Current debt | $355.70M | $228.20M | $178.30M | $162.50M | $534.20M | +55.9% |
| Long-term debt | $2.54B | $2.46B | $2.47B | $2.50B | $2.07B | +3.1% |
| Total debt | $3.08B | $2.87B | $2.83B | $2.84B | $2.79B | +7.0% |
| Total liabilities | $3.94B | $3.78B | $3.85B | $3.64B | $3.59B | +4.3% |
| Retained earnings | -$1.18B | -$1.09B | -$996.00M | -$865.30M | -$132.30M | -8.5% |
| Shareholder equity | $1.77B | $1.85B | $1.92B | $2.04B | $2.79B | -4.1% |
| Working capital | $383.20M | $414.60M | $481.20M | $598.80M | $139.40M | -7.6% |
| Net tangible assets | -$903.50M | -$668.80M | -$643.30M | -$571.60M | -$578.90M | -35.1% |
| Shares issued | 68.30M | 68.08M | 67.93M | 67.90M | 67.70M | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$92.90M | -$91.80M | -$130.70M | -$733.00M | -$255.40M | -1.2% |
| Depreciation & amortisation | $116.70M | $112.90M | $112.50M | $112.10M | $110.30M | +3.4% |
| Stock-based compensation | $12.00M | $10.70M | $10.80M | $10.70M | $12.80M | +12.1% |
| Change in working capital | -$134.70M | -$67.90M | $129.10M | -$134.80M | -$74.70M | -98.4% |
| Operating cash flow | -$110.60M | -$33.00M | $131.90M | -$45.50M | -$46.80M | -235.2% |
| Capital expenditure | -$25.50M | -$34.00M | -$45.30M | -$49.20M | -$37.50M | +25.0% |
| Investing cash flow | -$107.30M | -$34.00M | -$49.60M | -$53.90M | -$33.00M | -215.6% |
| Financing cash flow | $200.60M | $37.60M | -$11.10M | $46.00M | $103.30M | +433.5% |
| Free cash flow | -$136.10M | -$67.00M | $86.60M | -$94.70M | -$84.30M | -103.1% |
| End cash position | $123.40M | $140.40M | $169.80M | $98.10M | $151.70M | -12.1% |
Options analytics
Put / call volume
0.17
Call-heavy session
Put / call open interest
0.73
Positioning, not flow
Max pain
12.50
-0.6% from spot
ATM implied vol
65.2%
Nearest strike to spot
Skew (10% OTM)
+119.1%
Puts bid over calls
Call volume
100
Contracts, this expiry
Put volume
17
Contracts, this expiry
Heaviest call OI
12.50
307 contracts
Heaviest put OI
10.00
303 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.05 | 0.13 | +374.6% |
| Mar 2026 | 0.36 | -0.04 | -111.2% |
| Dec 2025 | 0.42 | 0.46 | +8.8% |
| Sep 2025 | 0.47 | 0.80 | +71.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.18 | 1 | $628.07M | -10.3% |
| Next quarter | 0.47 | 1 | $665.60M | -8.0% |
| Current year | 0.77 | 2 | $2.54B | -6.8% |
| Next year | 1.44 | 2 | $2.59B | +1.8% |
Analyst targets & ownership
Mean target$14.67
High target$20.00
Low target$12.00
Implied upside18.47%
Analyst count3
ConsensusHOLD
Strong buy / Buy0 / 1
Hold1
Sell / Strong sell0 / 1
Held by insiders0.90%
Held by institutions124.14%
Institutions holding335
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
10.98
+12.75% from price
SMA 20
11.12
+13.04% from price
SMA 50
13.43
-6.42% from price
SMA 100
14.10
-12.20% from price
SMA 200
17.81
-29.44% from price
EMA 12
11.32
+9.39% from price
EMA 26
11.88
+4.23% from price
EMA 50
12.86
-3.72% from price
RSI (14)
55.8
Neutral
MACD (12,26,9)
-0.56
Hist 0.30
ATR (14)
0.70
5.53% of price
Realised vol 30D
61.5%
Annualised
Bollinger upper
12.52
20, 2σ
Bollinger lower
9.72
20, 2σ
50 / 200 cross
Death
13.43 vs 17.81
Trend bias
Below 200
-29.44%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.49
More volatile than market
Correlation to SPY
0.36
Loosely linked
Realised vol 30D
61.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-71.8%
Peak to trough
Max drawdown 5Y
-94.3%
Peak to trough
ATR 14
0.70
5.53% of price
Beta (reported)
0.78
5Y monthly, from filing
Short interest
Shares short
14.19M
Prior 14.96M
Change vs prior
-5.2%
Shorts covering
% of float
28.21%
Heavily shorted
% of shares out
20.69%
Against total outstanding
Days to cover
10.5
Crowded exit
Float
61.17M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 8, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| Jul 1, 26 | JP Morgan | MAINTAINED | Underweight | Underweight |
| May 7, 26 | Jefferies | DOWNGRADE | Buy | Hold |
| May 6, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| Apr 10, 26 | UBS | MAINTAINED | Neutral | Neutral |
| Feb 12, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| Jan 21, 26 | UBS | MAINTAINED | Neutral | Neutral |
| Nov 7, 25 | JP Morgan | MAINTAINED | Underweight | Underweight |
| Nov 6, 25 | UBS | MAINTAINED | Neutral | Neutral |
| Oct 7, 25 | Citigroup | DOWNGRADE | Buy | Neutral |
| Aug 7, 25 | UBS | MAINTAINED | Neutral | Neutral |
| Aug 6, 25 | Citigroup | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-23
Periodic Financial Reports
10-Q · 2026-08-07
Corporate Changes & Voting Matters
8-K · 2026-08-06
Offering Registrations
S-8 · 2026-07-13
Corporate Changes & Voting Matters
8-K · 2026-06-23
Corporate Changes & Voting Matters
8-K · 2026-06-16
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-11
Periodic Financial Reports
10-Q · 2026-05-06
Headlines
2 Healthcare Stocks with Impressive Fundamentals and 1 Facing Challenges
StockStory · 12d ago
Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment
PR Newswire · 13d ago
Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know
StockStory · 13d ago
Point of Care Diagnostics Market Forecasts Growth from $20.63B (2026) to $31.46B by 2031, Profiling QuidelOrtho, Sysmex, HemoCue, Trinity Biotech & 15 Other Key Players
GlobeNewswire · 21d ago
3 Stocks Under $50 We Think Twice About
StockStory · 34d ago
Faster Answers, Better Decisions: ADLM 2026 Highlights
PR Newswire · 41d ago
1 Russell 2000 Stock Worth Your Attention and 2 That Underwhelm
StockStory · 42d ago
Here's What Is Shaping Abbott's Diagnostics Growth
Zacks · 44d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.